Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
Eligibility criteria
Qualifiers
Have Lp(a) ≥175 nanomoles per liter (nmol/L)
Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 years prior to screening
Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a history of ASCVD event
A high coronary artery calcium (CAC) score
Disqualifiers
Have experienced a major cardiovascular event or surgery, such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body, within 90 days prior to screening or occurring between screening and randomization
Are planning or expected to undergo a procedure to restore blood flow in the arteries or a major heart surgery during the study
Have uncontrolled high blood pressure
Have New York Heart Association (NYHA) class III or IV heart failure
Trial design
Treatments tested in this trial
- Muvalaplin
- Placebo
Treatment groups
10,450 Participants
are divided into 2 treatment groupsLocations
762Argentina
CEC - Consultorios de Especialidades Cardiovasculares8000, Bahía Blanca Argentina
Buenos Aires Macula S.A1061, Buenos Aires Argentina
Cardiología Palermo1425, Buenos Aires Argentina
CEMEDICC1407GTN, Buenos Aires Argentina
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov